| Biomarker ID | 1562 |
| PMID | 31069142 |
| Year | 2019 |
| Biomarker | WISP1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Increased with decreased BCR survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: HR: 5.83;Cohort 3: HR: [Univariate: 1.477 (95% CI: 1.014–2.150)] |
| Effect on Pathways | Pathway include: Wnt signaling pathway |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | MSKCC Prostate Oncogenome Project (n = 131) Cohort and the TCGA Prostate Adenocarcinoma Provisional Study (n = 363) were used for analysis. Further validation was performed on immunofluorescence dataset with 285 samples. In cohort 3: 168 did not experience BCR and 117 experienced BCR |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Cohort 1: p = 0.028;Cohort 3: p= 0.042 |
| Method Used | Immunofluorescence |
| Clinical | No |
| Remarks | Results did not reach statistical significance for Cohort 2 |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |